We confirmed that high expression levels of ERCC1 and GOF p53 mutants can contribute to the resistance of NSCLC cell lines to the above treatment, and combined screening for these two biomarkers might have great potential value in future clinical practice. Here, TP53 is linked to non-small cell lung carcinoma.